2219 (2219) Fair Value & Analysis

Healthcare · Market cap HK$1.7B

2 2219 2219 · HK

PriceHK$2.48

Fair ValueHK$5.91

Upside+138.3%

Quality60/100

Watch 2219 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$3.78 – HK$8.41

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −4.2% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$2.26 – HK$2.86 · fair‑value band HK$3.78 – HK$8.41 · the HK$2.48 price screens below the HK$5.91 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2219 (2219) currently trades at HK$2.48, while our model-based Fair Value estimate is HK$5.91 — implying the stock looks roughly 138.3% undervalued today. We read business quality at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 2219 generated revenue of HK$1.4B at a net margin of 13.5%. Revenue declined 1.4% year over year. It earns a return on equity of 7.5%. The balance sheet holds a net cash position of HK$279M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.4B

Revenue growth (YoY) -1.4%

Net margin 13.5%

Return on equity 7.5%

Free cash flow HK$113M FY2025

P/E ratio 8.3

More key figures

Operating margin 14.5%

EPS (TTM) HK$0.1600

Dividend yield 8.9%

EPS growth (YoY) +24.4%

Net cash HK$279M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2219 reported revenue of HK$1.4B in FY2025 versus HK$998M in FY2021, a compound +8.1%/yr. Reported net income was HK$183M in FY2025, compounding +3.2%/yr from FY2021.

Revenue +8.1%/yr

FY21 HK$998M

FY22 HK$990M

FY23 HK$1.4B

FY24 HK$1.4B

FY25 HK$1.4B

Net income +3.2%/yr

FY21 HK$162M

FY22 HK$188M

FY23 HK$229M

FY24 HK$195M

FY25 HK$183M

Is 2219 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$95.75	R$123.65	+29%
Fresenius SE FSNUY	$11.30	$8.61	-24%
5225 5225	8.67 MYR	3.08 MYR	-64%
IHHHF IHHHF	$1.71	$0.7400	-57%
Tenet Healthcare Corporation THC	$162.06	$282.55	+74%
Rede D'Or São Luiz S.A RDOR3	R$32.76	R$30.33	-7%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2219 (2219) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$5.91 versus a price of HK$2.48 — about +138% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 2219?

Our model-based fair value for 2219 is HK$5.91 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$2.48.

What is the quality score of 2219?

2219 has a Quality Score of 60/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2219 (2219)?

2219 reported trailing-twelve-month revenue of about HK$1.4B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2219?

The net profit margin of 2219 is about 13.5%, meaning it keeps roughly 13.5% of revenue as net income. Based on the latest reported figures.

Does 2219 pay a dividend?

2219 currently shows a dividend yield of about 8.90% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.